

# ENPP1 Inhibitor TXN10128

Txinno Bioscience Inc.



ONCOLOGY	Non-Clinical
Product Type	New Chemical Entity (NCE)
Indication	Colorectal cancer (+ various solid cancers)
Target	ENPP1
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• Cytosolic DNA in cancer cell activates STING pathway through cGAMP production by cGAS sensor.</li> <li>• ENPP1 hydrolyzes cGAMP, prevents STING activation and reduces anti-tumor immune response.</li> <li>• ENPP1 inhibitor restores STING signaling in TME, increases activities of NK cells/DC cells, converts cold tumor into hot tumor by inducing lymphocyte infiltration, and augments anti-tumor immune responses.</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>• TXN10128 is a potent and selective ENPP1 inhibitor that can exert immune responses in 3D co-culture condition.</li> <li>• TXN10128 augments synergistic tumor growth inhibition with anti-PD-L1 antibody and favorable TIL profile in MC38 syngeneic mouse model.</li> <li>• TXN10128 has promising drug-likeness and PK profile.</li> <li>• TXN10128 is a suitable candidate for clinical investigation as a combination partner with existing immunotherapies.</li> <li>• Preclinical studies for TXN10128 will be completed 4Q 2022 and phase 1 clinical trial will be started within 2023.</li> </ul>
Development Stage	Non-Clinical
Route of Administration	Oral q.d. (desired) or b.i.d.; combine with ICIs, XRT